Alluvi, known as BI 4744, offers a notable development in obesity care. This dual agonist targeting both GLP-1 and GIP receptors demonstrates remarkable efficacy in research studies, arguably surpassing existing GLP-1 https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/